Assunta Esposito

957 total citations
21 papers, 517 citations indexed

About

Assunta Esposito is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Assunta Esposito has authored 21 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Assunta Esposito's work include Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (12 papers) and Melanoma and MAPK Pathways (9 papers). Assunta Esposito is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (12 papers) and Melanoma and MAPK Pathways (9 papers). Assunta Esposito collaborates with scholars based in Italy, United States and Malaysia. Assunta Esposito's co-authors include Paolo A. Ascierto, Antonio Maria Grimaldi, Ester Simeone, Marcello Curvietto, Nicola Mozzillo, Marco Palla, Miriam Paone, Diana Giannarelli, Giuseppe Palmieri and Corrado Caracò and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Translational Medicine and Cancer Immunology Immunotherapy.

In The Last Decade

Assunta Esposito

20 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Assunta Esposito Italy	9	423	214	113	105	47	21	517
Candy Garcia United States	3	393 0.9×	207 1.0×	101 0.9×	81 0.8×	51 1.1×	3	484
Sang Hyung Lee South Korea	6	293 0.7×	171 0.8×	78 0.7×	96 0.9×	94 2.0×	7	441
David B. Page United States	5	448 1.1×	285 1.3×	73 0.6×	104 1.0×	34 0.7×	6	567
Fareeda Hosein United States	4	472 1.1×	190 0.9×	146 1.3×	119 1.1×	33 0.7×	8	581
Petros Fessas United Kingdom	8	341 0.8×	141 0.7×	133 1.2×	91 0.9×	49 1.0×	14	529
Cristina Migali Italy	12	376 0.9×	198 0.9×	86 0.8×	91 0.9×	37 0.8×	17	511
Giulia Mazzaschi Italy	11	444 1.0×	166 0.8×	254 2.2×	130 1.2×	58 1.2×	54	634
Alex De Caluwé Belgium	9	305 0.7×	116 0.5×	196 1.7×	104 1.0×	46 1.0×	25	523
Mario Liste-Hermoso United States	4	633 1.5×	181 0.8×	192 1.7×	88 0.8×	31 0.7×	7	756
M.T. Spiotto United States	3	521 1.2×	429 2.0×	85 0.8×	103 1.0×	24 0.5×	4	642

Countries citing papers authored by Assunta Esposito

Since Specialization

Citations

This map shows the geographic impact of Assunta Esposito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Assunta Esposito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Assunta Esposito more than expected).

Fields of papers citing papers by Assunta Esposito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Assunta Esposito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Assunta Esposito. The network helps show where Assunta Esposito may publish in the future.

Co-authorship network of co-authors of Assunta Esposito

This figure shows the co-authorship network connecting the top 25 collaborators of Assunta Esposito. A scholar is included among the top collaborators of Assunta Esposito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Assunta Esposito. Assunta Esposito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Esposito, Assunta, C. Giugliano, Santolo Cozzolino, et al.. (2025). Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center’s real-world approach. PubMed. 7. 100108–100108.

Varricchio, Silvia, Assunta Esposito, Angelica Perna, et al.. (2024). The oral microbiome and its role in oral squamous cell carcinoma: a systematic review of microbial alterations and potential biomarkers. Pathologica. 116(6). 338–357. 3 indexed citations

Mallardo, Domenico, Francesca Sparano, Maria Grazia Vitale, et al.. (2024). Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma. Cancer Immunology Immunotherapy. 73(8). 160–160. 4 indexed citations

Amoroso, Vito, Andrea Alberti, Assunta Esposito, et al.. (2023). Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open. 8(2). 100787–100787. 42 indexed citations

Simeone, Ester, Giosuè Scognamiglio, Mariaelena Capone, et al.. (2021). A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine. 19(1). 17–17. 5 indexed citations

Trojaniello, Claudia, et al.. (2020). Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy. 20(4). 289–304. 15 indexed citations

Capone, Mariaelena, Diana Giannarelli, Claudia Sorrentino, et al.. (2020). Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. Journal of Translational Medicine. 18(1). 121–121. 28 indexed citations

Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2017). Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. OncoImmunology. 6(3). e1283462–e1283462. 30 indexed citations

Grimaldi, Antonio Maria, Ester Simeone, Lucia Festino, et al.. (2015). Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P186–P186. 6 indexed citations

10.

Simeone, Ester, Antonio Maria Grimaldi, Lucia Festino, et al.. (2015). Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P134–P134. 1 indexed citations

11.

Grimaldi, Antonio Maria, Ester Simeone, Diana Giannarelli, et al.. (2014). Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology. 3(5). e28780–e28780. 290 indexed citations

12.

Simeone, Ester, Antonio Maria Grimaldi, Assunta Esposito, et al.. (2014). Serious haematological toxicity during and after ipilimumab treatment: a case series. Journal of Medical Case Reports. 8(1). 240–240. 41 indexed citations

13.

Grimaldi, Antonio Maria, Ester Simeone, Diana Giannarelli, et al.. (2014). Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg. Journal of Translational Medicine. 12(Suppl 1). O6–O6. 3 indexed citations

14.

Simeone, Ester, Maria Fiammetta Romano, Antonio Maria Grimaldi, et al.. (2014). High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab. Journal for ImmunoTherapy of Cancer. 2(S3). 1 indexed citations

15.

Alvarado, Ryan, Santosh Putta, Ester Simeone, et al.. (2014). Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. Journal of Translational Medicine. 12(Suppl 1). O13–O13. 11 indexed citations

16.

Ascierto, Paolo A., Ester Simeone, Antonio Maria Grimaldi, et al.. (2013). Do BRAF inhibitors select for populations with different disease progression kinetics?. Journal of Translational Medicine. 11(1). 61–61. 18 indexed citations

17.

Grimaldi, Antonio Maria, Ester Simeone, Diana Giannarelli, et al.. (2013). The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg. Journal for ImmunoTherapy of Cancer. 1(S1). 3 indexed citations

18.

Alvarado, Ryan, Andrew Conroy, Santosh Putta, et al.. (2013). Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. Journal for ImmunoTherapy of Cancer. 1(S1). 1 indexed citations

19.

Simeone, Ester, Giusy Gentilcore, Corrado Caracò, et al.. (2013). Combination therapy with ipilimumab and electrochemotherapy: Preliminary efficacy results and correlation with immunologic parameters.. Journal of Clinical Oncology. 31(15_suppl). e20031–e20031. 3 indexed citations

20.

Simeone, Ester, Giusy Gentilcore, Antonio Daponte, et al.. (2012). Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. Journal of Clinical Oncology. 30(15_suppl). 8573–8573. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact